Ligand Pharmaceuticals Milestone Payment

Summary by AI BETAClose X

Arecor Therapeutics plc has received a $0.5 million commercial milestone payment from Ligand Pharmaceuticals, representing the first such payment under their royalty financing agreement. This payment is related to the sale of global royalty rights for AT220 and potential milestone fees for AT292. Arecor initially received $7.0 million upfront and anticipates another $0.5 million in the second half of 2026, with the remaining $3 million contingent on future commercial milestones for AT220 and AT292. These non-dilutive funds are being utilized to accelerate Arecor's lead program, AT278, an ultra-concentrated and ultra-rapid-acting insulin, with a Phase 2 clinical trial anticipated to commence in the second half of 2026.

Disclaimer*

UK 100

Latest directors dealings